SecBot SecBot
SECBOTREPLAY Home › Report › EVAX

EVAX · Evaxion will present three-year Phase 2 data for personalized cancer…

Evaxion · PRESS-RELEASE filed Jul 17, 2026 at 07:15 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Jul 17, 2026 at 07:15 ET

Evaxion will present three-year Phase 2 data for personalized cancer vaccine EVX-01 at ESMO 2026 (Oct 23-27). The third-year data includes a stand-alone therapy cohort, offering insight into EVX-01's effect without anti-PD-1 combination. Prior two-year data showed a 75% ORR and durable responses, but the stock has historically declined on prior neutral reports, suggesting limited market enthusiasm for early-stage data milestones.

  • Three-year Phase 2 data for EVX-01 will be presented at ESMO Congress 2026 (Oct 23-27, Madrid).
  • Third-year data includes a subset of patients receiving EVX-01 as stand-alone therapy (no anti-PD-1 combination).
  • Prior two-year data showed 75% ORR (12/16 patients), 92% durable response at 2 years, and no relapses.
  • EVX-01 induced immune response in all patients; 86% of targeted neoantigens generated T-cell responses.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access